百晓学者学者目录

涂亚林

副教授，暨南大学

精选作品

期刊论文

2026

Abstract P59: Targeting TGF-β signaling pathway to reverse immune checkpoint blockade resistance in hepatocellular carcinoma

Yan Liu, Hui Yue, Yalin Tu, Ya-Xian Wang, Siyuan Huang, Haoran Wu, Xiaohang Long, C. Tong, A. Cheng

Cancer Research

DOI

2026

Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling.

Zhixian Liang, Xiaohang Long, Zhe-Wen Xiong, P. Wong, Siyuan Huang, Si-Yun Chen, Yiling Zhang, Lingyun Zhang, C. Leung, Jianquan Cao, Haoran Wu, Huiyu Yue, Zi-Hui Zhao, Yalin Tu, Baoyi Yin, Weiqin Yang, Jing Wang, Shu-Fen Chen, Xuerao Zhang, Yuk-Wah Tsang, Chengpeng Zhong, Xiaoyu Liu, Li-Peng Ding, Jia-Hua Lu, Willis Wai-Yiu Si-Tou, Yan Liu, Ya-Xian Wang, Ying-Nan Lin, Jian-Xin Liang, Weida Ren, Joaquim Vong, M. Tong, Xiaoyu Tian, H. Hui, Jing-Ying Zhou, S. Ngai, Shelly Ni, Ka-Fai To, T. Braun, Joseph Jao-Yiu Sung, S. Chan, A. S. Cheng

Cancer Cell

DOI

2026

Abstract 7146: Targeting tumor macrophage TGF-β signaling overcomes immunotherapy resistance in hepatocellular carcinoma

Hui Yue, Yan Liu, Han Wang, Yalin Tu, Ya-Xian Wang, Siyuan Huang, Haoran Wu, Xiaohang Long, C. Tong, Alfred Sze-Lok Cheng

Cancer Research

DOI

2026

Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma

Changfa Zhang, Yalei Wen, Jianqiao Yi, Xuan Wang, Junping Pei, Yalin Tu, Ren‐Wang Jiang, Tongzheng Liu, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance

Shuang Xiang, Xiaojuan Chen, Jieying Lin, Xiaojing Lin, Qianmeng Lin, Xiaojuan Song, Ling Yan, Haoran Peng, Zhengchao Tu, Adam Vorn Patterson, Jeff Bruce Smaill, Yalin Tu, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors

Jia-Hua Lu, T. T. Chan, Yun Wang, Jing-Ya Wang, Zhe-Wen Xiong, Jingqing Li, Yixuan Zhang, Huanyu Wang, Jin-Tian Chen, Weiqin Yang, Jing Wang, Yalin Tu, Howard Leung, R. W. Lung, Wei Kang, M. Tong, D. Wang, Qi-Nian Wu, Zhaocheng Zeng, A. S. Cheng, Ka-Fai To, A. Chan, Jing-Ying Zhou

Cancer Research

DOI

2025

IDDF2025-ABS-0335 Unraveling the role of chromatin organization in immunotherapy resistance of hepatocellular carcinoma

Si-Yun Chen, Ying-Nan Lin, Chengpeng Zhong, Yalin Tu, Haoran Wu, Yiling Zhang, Jia Wang, Alfred S. Cheng

Basic Hepatology

DOI

2025

Abstract 2751: Role of transcriptional regulation in chromatin architecture and immunotherapy resistance of hepatocellular carcinoma

Si-Yun Chen, Ying-Nan Lin, Chengpeng Zhong, Yalin Tu, Haoran Wu, Yiling Zhang, Jia Wang, Alfred Sze Lok Cheng

Cancer Research

DOI

2025

Abstract 2186: Deciphering the regulation and function of lipid associated macrophages in immunotherapy resistance of hepatocellular carcinoma

Xiaohang Long, S. Chan, Siyuan Huang, Joaquim Si Long Vong, Xiaoyu Zhan, Yalin Tu, Joseph JY Sung, A. S. Cheng

Cancer Research

DOI

2024

Abstract 1424: Epigenetic activation of tumoral IFNγresponse and pyroptosis overcomes immunotherapy resistance in hepatocellular carcinoma

Yalin Tu, Haoran Wu, Chengpeng Zhong, Zhe-Wen Xiong, Jing Wang, P. Wong, Weiqin Yang, Jia-Hua Lu, Zhixian Liang, Shu-Fen Chen, Lingyun Zhang, Si-Yun Chen, Jingying Zhou, Ka-Fai To, Joseph J. Y. Sung, S. Chan, David Kerr, N. La Thangue, A. S. Cheng

Cancer Research

DOI

2024

Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma

Yalin Tu, Haoran Wu, Chengpeng Zhong, Yan Liu, Zhe-Wen Xiong, Si-Yun Chen, Jing Wang, P. Wong, Weiqin Yang, Zhixian Liang, Jia-Hua Lu, Shu-Fen Chen, Lingyun Zhang, Yu Feng, Willis Wai-Yiu Si-Tou, Baoyi Yin, Ying-Nan Lin, Jian-Xin Liang, Liying Liang, Joaquim S. L. Vong, Weida Ren, Tsz-Tung Kwong, Howard Leung, Ka-Fai To, Stephianie Ma, M. Tong, Hanyong Sun, Q. Xia, Jing-Ying Zhou, David Kerr, N. La Thangue, Joseph J. Y. Sung, S. Chan, A. S. Cheng

Gut

DOI

2023

IDDF2023-ABS-0174 Epigenetic activation of tumoral INFγ response and pyroptosis overcomes immunotherapy resistance in hepatocellular carcinoma

Yalin Tu, Chengpeng Zhong, Haoran Wu, Zhe-Wen Xiong, Jing Wang, Patrick Pak-chun Wong, Weiqin Yang, Jia-Hua Lu, Zhixian Liang, Shu-Fen Chen, Lingyun Zhang, Si-Yun Chen, Jingying Zhou, Ka-Fai To, J. Sung, S. Chan, D. Kerr, N. La Thangue, A. S. Cheng

Basic Hepatology

DOI

2023

Tumor cell-macrophage crosstalk promotes immunotherapy resistance via lipid metabolism

Zhixian Liang, Jianquan Cao, Wen-Shu Tang, Haoran Wu, Yalin Tu, Zhe-Wen Xiong, Lingyun Zhang, Jingying Zhou, S. Chan, A. Cheng

Journal of Immunology

DOI

2023

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Zhe-Wen Xiong, S. Chan, Jingying Zhou, Joaquim S. L. Vong, Tsz-Tung Kwong, Xuezhen Zeng, Haoran Wu, Jianquan Cao, Yalin Tu, Yu Feng, Weiqin Yang, P. Wong, Willis Wai-Yiu Si-Tou, Xiaoyu Liu, Jing Wang, Wen-Shu Tang, Zhixian Liang, Jia-Hua Lu, Ka-Man Li, Jie-Ting Low, Michael W. Y. Chan, H. H. Leung, A. Chan, Ka-Fai To, Kevin Y. Yip, Yuk Ming Dennis Lo, J. Sung, A. S. Cheng

Gut

DOI

2022

IDDF2022-ABS-0195 Tumor cells-derived lipids modulate macrophage activity to regulate immunotherapy resistance of hepatocellular carcinoma

Zhixian Liang, Jianquan Cao, Wen-Shu Tang, Haoran Wu, Yalin Tu, Zhe-Wen Xiong, Jingying Zhou, S. Chan, A. S. Cheng

Basic Hepatology

DOI

2022

IDDF2022-ABS-0103 A selective class I HDAC inhibitor recovers intratumoral interferon signaling to overcome immune-checkpoint blockade resistance in hepatocellular carcinoma

Yalin Tu, Zhe-Wen Xiong, Chengpeng Zhong, Haoran Wu, Jing Wang, P. Wong, Weiqin Yang, Jingying Zhou, Ka-Fai To, Joseph J. Y. Sung, S. Chan, D. Kerr, N. La Thangue, A. S. Cheng

Basic Hepatology

DOI

2021

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

Weiqin Yang, Yu Feng, Jingying Zhou, O. K. Cheung, Jianquan Cao, Jing Wang, Wen-Shu Tang, Yalin Tu, Liang-Liang Xu, Feng Wu, Z. Tan, Hanyong Sun, Yuan Tian, J. Wong, P. Lai, S. Chan, A. Chan, P. Tan, Zhi-Wei Chen, J. J. Sung, Kevin Y. Yip, Ka F. To, A. Cheng

Science Translational Medicine

DOI

2021

Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis.

Feng Wu, Liang-Liang Xu, Yalin Tu, Otto K. Cheung, Lemuel L. M. Szeto, Myth T. S. Mok, Weiqin Yang, Wei Kang, Qin Cao, P. Lai, S. Chan, P. Tan, J. J. Sung, Kevin Y. Yip, A. S. Cheng, Ka-Fai To

Cancer Letters

DOI

2020

IDDF2020-ABS-0201 Targeting hepatoma-intrinsic pparγ signaling overcomes immune checkpoint therapy resistance by inflaming the tumor microenvironment

Zhe-Wen Xiong, S. Chan, Jingying Zhou, Jianquan Cao, Joaquim S. L. Vong, Xuezhen Zeng, Yalin Tu, Yu Feng, Kevin Y. Yip, J. J. Sung, Alfred S. L. Cheng

DOI

预印本

2026

Remote-site Allosteric Control of DFG Dynamics Enables Rational Design of the First Reversible Macrocyclic FGFR2 Inhibitors

Shuang Xiang, Shengjie Huang, Xiaojuan Chen, Yalin Tu, Yuhan Wang, Ling Yan, Lin Zhang, Xiaojuan Song, Jieying Lin, Xiaojing Lin, Wuqing Deng, Zhengchao Tu, Zhi-Min Zhang, Adam Vorn Patterson, Jeff Bruce Smaill, Yongheng Chen, Yang Zhou, Xiaoyun Lu

ChemRxiv

DOI

书籍章节

2026

Small macrocyclic inhibitors of kinase

Jianqiao Yi, Yalin Tu, Xiaoyun Lu

Elsevier eBooks

DOI

研究方向

肿瘤（特别是HCC）免疫治疗耐药机制解析及新干预靶点的发现肿瘤的表观遗传调控小分子靶向抗肿瘤药物的作用及机制研究

此主页由公开资料整理，尚未经学者本人认领。